A Virtual Reality Platform for Parkinson Disease
Episode 78, Dec 02, 2022, 11:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders
Episode Breakdown:
In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus page: neurologylive.com/clinical/movement-disorders
Episode Breakdown:
- 1:20 – An overview of the state of virtual reality in medicine
- 2:20 – The Cleveland Clinic Virtual Reality Shopping platform
- 6:45 – The importance of mimicking the details of reality
- 8:05 – Misconceptions and surprises with VR for Parkinson disease
- 11:45 – Neurology News Minute
- 15:05 – How VR can be used in prodromal Parkinson disease
- 19:00 – Biomarkers for Parkinson disease
- 21:15 – Using VR as a targeted therapy
- 23:20 – The opportunity in medicine with VR systems
This episode is brought to you by the Medical World News streaming service. Check out new content and shows every day, only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype
- Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
- Duchenne Gene Therapy SRP-9001 Wins Priority Review
- Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses
- Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.